Skip to main content

Advertisement

Table 4 Progression-Free Survival in Pazopanib Recipients by Dose Modifications (ITT Population)

From: Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

Dose Modifications n (%) mPFS, weeks (95% CI)
Dose reductions
 No dose reduction 154 (100) 11.9 (8.9–19.3)
  Progressed or Died 104 (68)  
  ≥ 1 dose reductions 92 (100) 27.7 (21.1–35.7)
  Progressed or Died 59 (64)  
 1 dose reduction 54 (100) 27.1 (20.1–35.7)
  Progressed or Died 29 (54)  
 2 or more dose reductions 38 (100) 28.1 (20.1–38.1)
  Progressed or Died 30 (79)  
Dose interruptions
 No dose interruption 107 (100) 11.0 (8.1–19.3)
  Progressed or Died 71 (66)  
  ≥ 1 dose interruptions 139 (100) 21.3 (20.1–27.7)
  Progressed or Died 92 (66)  
 1 dose interruption 69 (100) 20.0 (12.4–21.3)
  Progressed or Died 45 (65)  
 2 or more dose interruptions 70 (100) 27.7 (21.0–35.6)
  Progressed or Died 47 (67)  
  1. CI confidence interval, ITT intention to treat